Epicatechin - Cardero Therapeutics

Drug Profile

Epicatechin - Cardero Therapeutics

Alternative Names: (+)- Epicatechin

Latest Information Update: 18 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cardero Therapeutics
  • Developer Cardero Therapeutics; Mayo Clinic; University of California, Davis
  • Class Antibacterials
  • Mechanism of Action Mitochondrial protein modulators; Oxidoreductase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Duchenne muscular dystrophy; Friedreich's ataxia
  • Preclinical Heart failure; Mitochondrial disorders

Most Recent Events

  • 01 Dec 2017 University of California and Cardero Therapeutics completes a phase II trial in Duchenne muscular dystrophy in USA (PO) (NCT03236662)
  • 15 Dec 2016 Biomarkers information updated
  • 01 Nov 2016 Phase-I/II clinical trials in Duchenne muscular dystrophy (In children, In adolescents) in USA (PO) (NCT02964377)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top